vs
Adaptive Biotechnologies Corp（ADPT）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是REGIS CORP的1.3倍（$71.7M vs $57.1M），REGIS CORP净利率更高（0.8% vs -18.9%，领先19.7%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs 22.3%），Adaptive Biotechnologies Corp自由现金流更多（$1.4M vs $891.0K），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 7.8%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
ADPT vs RGS — 直观对比
营收规模更大
ADPT
是对方的1.3倍
$57.1M
营收增速更快
ADPT
高出28.8%
22.3%
净利率更高
RGS
高出19.7%
-18.9%
自由现金流更多
ADPT
多$528.0K
$891.0K
两年增速更快
ADPT
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $57.1M |
| 净利润 | $-13.6M | $456.0K |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | 10.8% |
| 净利率 | -18.9% | 0.8% |
| 营收同比 | 51.0% | 22.3% |
| 净利润同比 | 59.7% | -94.0% |
| 每股收益（稀释后） | $-0.08 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTRGS
| Q4 25 | $71.7M | $57.1M | ||
| Q3 25 | $94.0M | $59.0M | ||
| Q2 25 | $58.9M | $60.4M | ||
| Q1 25 | $52.4M | $57.0M | ||
| Q4 24 | $47.5M | $46.7M | ||
| Q3 24 | $46.4M | $46.1M | ||
| Q2 24 | $43.2M | $49.4M | ||
| Q1 24 | $41.9M | $49.2M |
净利润ADPTRGS
| Q4 25 | $-13.6M | $456.0K | ||
| Q3 25 | $9.5M | $1.4M | ||
| Q2 25 | $-25.6M | $116.5M | ||
| Q1 25 | $-29.9M | $250.0K | ||
| Q4 24 | $-33.7M | $7.6M | ||
| Q3 24 | $-32.1M | $-853.0K | ||
| Q2 24 | $-46.2M | $91.2M | ||
| Q1 24 | $-47.5M | $-2.3M |
毛利率ADPTRGS
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTRGS
| Q4 25 | -17.8% | 10.8% | ||
| Q3 25 | 10.9% | 10.0% | ||
| Q2 25 | -42.5% | 12.1% | ||
| Q1 25 | -56.4% | 8.8% | ||
| Q4 24 | -71.3% | 11.8% | ||
| Q3 24 | -70.3% | 4.6% | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | 8.3% |
净利率ADPTRGS
| Q4 25 | -18.9% | 0.8% | ||
| Q3 25 | 10.2% | 2.3% | ||
| Q2 25 | -43.5% | 192.9% | ||
| Q1 25 | -56.9% | 0.4% | ||
| Q4 24 | -71.0% | 16.4% | ||
| Q3 24 | -69.1% | -1.9% | ||
| Q2 24 | -107.0% | 184.7% | ||
| Q1 24 | -113.5% | -4.7% |
每股收益（稀释后）ADPTRGS
| Q4 25 | $-0.08 | $0.16 | ||
| Q3 25 | $0.06 | $0.49 | ||
| Q2 25 | $-0.17 | $43.67 | ||
| Q1 25 | $-0.20 | $0.08 | ||
| Q4 24 | $-0.22 | $2.71 | ||
| Q3 24 | $-0.22 | $-0.36 | ||
| Q2 24 | $-0.31 | $38.40 | ||
| Q1 24 | $-0.33 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $218.8M | $188.7M |
| 总资产 | $512.7M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资ADPTRGS
| Q4 25 | $70.5M | $18.4M | ||
| Q3 25 | $55.0M | $16.6M | ||
| Q2 25 | $43.2M | $17.0M | ||
| Q1 25 | $50.6M | $13.3M | ||
| Q4 24 | $47.9M | $10.2M | ||
| Q3 24 | $38.1M | $6.3M | ||
| Q2 24 | $59.8M | $10.1M | ||
| Q1 24 | $71.2M | $5.9M |
总债务ADPTRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益ADPTRGS
| Q4 25 | $218.8M | $188.7M | ||
| Q3 25 | $204.4M | $187.6M | ||
| Q2 25 | $179.7M | $185.6M | ||
| Q1 25 | $190.4M | $68.6M | ||
| Q4 24 | $202.7M | $66.7M | ||
| Q3 24 | $223.8M | $56.4M | ||
| Q2 24 | $241.6M | $56.8M | ||
| Q1 24 | $274.9M | $-35.8M |
总资产ADPTRGS
| Q4 25 | $512.7M | $588.3M | ||
| Q3 25 | $490.6M | $592.1M | ||
| Q2 25 | $496.6M | $599.0M | ||
| Q1 25 | $510.9M | $511.2M | ||
| Q4 24 | $539.4M | $530.1M | ||
| Q3 24 | $558.5M | $508.9M | ||
| Q2 24 | $584.9M | $530.5M | ||
| Q1 24 | $620.3M | $543.7M |
负债/权益比ADPTRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $891.0K |
| 自由现金流率自由现金流/营收 | 2.0% | 1.6% |
| 资本支出强度资本支出/营收 | 0.9% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $14.9M |
8季度趋势，按日历期对齐
经营现金流ADPTRGS
| Q4 25 | $2.1M | $1.7M | ||
| Q3 25 | $-7.1M | $2.3M | ||
| Q2 25 | $-12.4M | $6.8M | ||
| Q1 25 | $-28.5M | $6.2M | ||
| Q4 24 | $-12.5M | $2.1M | ||
| Q3 24 | $-27.1M | $-1.3M | ||
| Q2 24 | $-17.3M | $5.1M | ||
| Q1 24 | $-38.4M | $-277.0K |
自由现金流ADPTRGS
| Q4 25 | $1.4M | $891.0K | ||
| Q3 25 | $-7.5M | $1.9M | ||
| Q2 25 | $-13.1M | $6.2M | ||
| Q1 25 | $-29.7M | $5.9M | ||
| Q4 24 | $-12.6M | $1.7M | ||
| Q3 24 | $-27.4M | $-1.4M | ||
| Q2 24 | $-19.0M | $5.1M | ||
| Q1 24 | $-39.9M | $-326.0K |
自由现金流率ADPTRGS
| Q4 25 | 2.0% | 1.6% | ||
| Q3 25 | -8.0% | 3.2% | ||
| Q2 25 | -22.2% | 10.3% | ||
| Q1 25 | -56.7% | 10.3% | ||
| Q4 24 | -26.5% | 3.6% | ||
| Q3 24 | -59.0% | -3.0% | ||
| Q2 24 | -44.1% | 10.3% | ||
| Q1 24 | -95.2% | -0.7% |
资本支出强度ADPTRGS
| Q4 25 | 0.9% | 1.4% | ||
| Q3 25 | 0.4% | 0.7% | ||
| Q2 25 | 1.1% | 0.9% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 4.0% | 0.0% | ||
| Q1 24 | 3.6% | 0.1% |
现金转化率ADPTRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | -0.75× | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
